# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Brian Cheng maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from ...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains ...
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(...
iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...
- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab ...
JP Morgan analyst Daniel Wolle maintains ITeos Therapeutics (NASDAQ:ITOS) with a Overweight and lowers the price target from...
ITeos Therapeutics (NASDAQ:ITOS) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...